• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    D

    Danbury Hospital

    EST. 1885
    1,135论文总数
    1.4万引用总数

    Danbury Hospital is a 456-bed hospital in Danbury, Connecticut serving patients in Fairfield County, Connecticut, as well as Westchester County and Putnam County, New York.The hospital has 3,300 employees and is part of the Nuvance Health system. John M. Murphy, M.D. is CEO of Nuvance Health, and previously served as president and CEO of Western Connecticut Health Network, which merged with Health Quest in early 2019 to form Nuvance Health.

    论文量&引用量时间轴

    机构学者

    论文(1135)

    年份
    起
    –
    止
    排序
    1Applicant Selection and Ranking in Breast Surgical Oncology Fellowships: A National Survey of Program Leadership.
    Joyce L. Eum,Cara M. Hannigan,Sydney H. Smilen, Susan K. Boolbol, Carinne W. Anderson

    BACKGROUND:Breast surgical oncology was the most competitive surgical fellowship match in 2025, with a record low of 61% of applicants successfully matched. Previous studies evaluated the attitudes of program directors on the selection and ranking criteria of candidates. This study evaluates the perspectives of both program directors and associate program directors on the selection and ranking process because of the increasing competitiveness of the field. METHODS:An anonymous, web-based survey was sent to all breast surgical oncology fellowship program leadership. The survey consisted of 24 questions. Survey analysis was performed using descriptive statistics. RESULTS:Of 65 programs, 76.9% responded; 50 program directors and 26 associate program directors participated. Over half of programs (57.9%) engaged in holistic review of applicants before offering an interview and did not have formal screening criteria. For most programs (84%), additional faculty members beyond program leadership contributed to the rank list. Interview performance was the most important factor (65.8%) in the formation of the rank list. DISCUSSION:Compared with prior years, breast surgical oncology fellowship directors reported fewer screening metrics before extending an interview. In rank list formation, there continues to be a strong majority consensus with previous years and among other surgical subspecialties that interview performance has the largest impact. An improved understanding of the application and rank list process enables both applicants and program directors to better prepare for a successful match.

    2026Annals of Surgical Oncology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Impact of Sodium-glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes of Prostate Cancer Patients Receiving Gonadotropin-Releasing Hormone Agonists
    Zhiting Tang,Yu-Cheng Chang,Kuan-Yu Chi, Yu Chang, Tsae-Ni Lee,Chieh-Lien Hsiao,Cho-Hung Chiang,Qian Wang,Albert Jang,Cho-Han Chiang
    2026European journal of preventive cardiology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Risk of Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Combination-Based Immunotherapy.
    Yu-Cheng Chang, Hao-Kuen Lin, Joseph Piwowarski, Yu-Che Lee, Chun-Yu Peng, Wenli Gao,Cho-Han Chiang
    2026British journal of haematology(2026)
    引用
    AI阅读
    加入学术空间
    4Over-the-scope Clips Versus Standard Endoscopic Therapy As First-Line Treatment for Bleeding Peptic Ulcer Disease: a Systematic Review and Meta-Analysis
    Hazem Abosheaishaa, Mohammed Y Youssef,Mohamed H Eldesouki, Mohamad Elgozair, Mina Iskander, Hossam Elnaggar, Layth Alzubaidy, Sharif Abbas, Ahmed Elsayed Alzamzamy, Arnold Forlemu,Madhavi Reddy

    Background:Peptic ulcer bleeding remains a significant cause of non-variceal upper gastrointestinal bleeding (NVUGIB). While over-the-scope clips (OTSC) are increasingly used as rescue therapy, their efficacy as first-line treatment remains unclear. The aim of this study is to evaluate the efficacy and safety of OTSC compared to standard endoscopic therapy (SET) as a first-line treatment in patients with bleeding peptic ulcer disease (PUD). Methods:A systematic literature search was conducted across MEDLINE, Embase, Scopus, and Web of Science databases up to March 13, 2026. Studies comparing OTSC and SET in bleeding PUD were included. Primary outcome was Clinical Success. Secondary outcomes included primary and technical success, need for surgery or re-therapy, mortality, hospital stay, and adverse events. Meta-analyses were performed using a random-effects model. Results:Six studies [3 randomized controlled trials (RCTs), 3 observational] comprising 454 patients were included. OTSC significantly improved clinical success [risk ratio (RR) =1.16, 95% confidence interval (CI): 1.06-1.27, P=0.002]. OTSC also significantly reduced overall bleeding (RR =0.46, 95% CI: 0.25-0.82, P=0.009). No statistically significant differences were observed in primary success, technical success, 7- or 30-day rebleeding, need for re-therapy, surgical intervention, in-hospital mortality, total mortality, adverse events, or hospital stay. Conclusions:OTSC is associated with significantly higher clinical success and lower overall bleeding rates compared to SET in bleeding PUD. Secondary outcomes, including rebleeding, re-intervention, and mortality, trended in favour of OTSC but did not reach statistical significance, likely reflecting limited power. These findings support OTSC as a promising first-line option. Further large-scale RCTs are warranted to confirm these results and guide clinical implementation.

    2026Annals of translational medicine(2026)
    引用
    AI阅读
    加入学术空间
    5The PDGFB–DDX5 Axis Contributes to Breast Cancer Radioresistance Through HR-associated DNA Repair
    Yixin Cheng, Xuefei Liu,Jingyun Peng,Chun Wu,Zhihui Zhang, Yingyi Li, Siqi Chen,Yulin Huang, Weihong Zheng,Ying Wang,Guanqiao Li, Yonghao Chen,

    Abstract Radioresistance remains a major barrier to effective breast cancer treatment, yet the molecular programs underlying acquired resistance remain incompletely understood. By establishing and characterizing radioresistant breast cancer cell models across multiple molecular subtypes, we revealed enhanced DNA repair capacity and epithelial-mesenchymal transition features in resistant cells. Transcriptomic profiling and functional validation identified platelet-derived growth factor B (PDGFB) as a key regulator of radioresistance. High PDGFB expression was associated with adverse outcomes across independent breast cancer cohorts, including a radiotherapy-treated subgroup. Mechanistically, PDGFB associated with DEAD-box RNA helicase 5 (DDX5) and stabilized DDX5 by limiting its ubiquitin-proteasome-mediated degradation. PDGFB depletion impaired homologous recombination (HR) efficiency, delayed DNA damage resolution, reduced RAD51 foci formation, and resensitized radioresistant cells to irradiation in vitro and in vivo. Conversely, DDX5 overexpression partially restored HR signaling, DNA damage resolution, and clonogenic survival in PDGFB-depleted cells. These findings uncovered a PDGFB-DDX5 regulatory axis that preferentially targets homologous recombination-associated DNA repair and contributes to breast cancer radioresistance. Implications: This study demonstrates the PDGFB–DDX5 axis as a crucial mechanism contributing to radioresistance by preferentially affects HR–mediated DNA damage repair, which can be therapeutically explored for overcoming radioresistance in breast cancer.

    2026Molecular Cancer Research(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1135 篇论文

    合作机构(100)

    Nuvance Health合作论文 31
    台湾大学医院合作论文 30
    耶鲁大学合作论文 24
    康涅狄格大学合作论文 20
    佛蒙特大学合作论文 20
    哥伦比亚大学合作论文 16
    堪萨斯大学合作论文 15
    布法罗大学,纽约州立大学合作论文 15
    Western Connecticut Health Network合作论文 14
    Mount Auburn Hospital合作论文 14

    机构统计